Karyopharm begins pivotal phase 3 study of XPO1 inhibitor selinexor and ruxolitinib in JAK inhibitor naive myelofibrosis

Press/Media

Period	29 Jun 2023

Media coverage

Title	Karyopharm begins pivotal phase 3 study of XPO1 inhibitor selinexor and ruxolitinib in JAK inhibitor naive myelofibrosis
Media name/outlet	PharmaBiz
Country/Territory	India
Date	29/06/23
URL	metabase.moreover.com/noarticleurl?type=psh&lni=68K6-V7J1-JB5M-W2HS-00000-00
Persons	John Mascarenhas